<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05106335</url>
  </required_header>
  <id_info>
    <org_study_id>SHR-1210-III-332</org_study_id>
    <nct_id>NCT05106335</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC</brief_title>
  <official_title>A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer Who Progressed on Prior Immune Checkpoint Inhibitor Treatment and Platinum-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, international, multi-center, phase III trial to evaluate&#xD;
      the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as&#xD;
      subsequent therapy in Advanced NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Camrelizumab Combined with Famitinib Malate Versus Docetaxel</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS</measure>
    <time_frame>up to 4 years</time_frame>
    <description>OS is the time interval from the date of randomization to death due to any reason or lost of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Progression-Free-Survival, defined as the time from randomization to the first occurrence of disease progression with use of RECIST v1.1 or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Objective Response Rate, determined using RECIST v1.1 criteria, defined as best overall response (CR or PR) across all assessment time points.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DoR</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Duration of Response, determined using RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Disease Control Rate, determined using RECIST v1.1 criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTF</measure>
    <time_frame>up to 4 years</time_frame>
    <description>Time to Treatment Failure, defined as the time from randomization to treatment discontinuation.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">524</enrollment>
  <condition>Advanced NSCLC</condition>
  <arm_group>
    <arm_group_label>Treatment Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>camrelizumab + famitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>famitinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>docetaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>camrelizumab + famitinib</intervention_name>
    <description>camrelizumab for intravenous injection; famitinib malate capsules for oral administration</description>
    <arm_group_label>Treatment Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>famitinib</intervention_name>
    <description>famitinib malate capsules for oral administration</description>
    <arm_group_label>Treatment Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <description>docetaxel for intravenous injection</description>
    <arm_group_label>Treatment Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed metastatic or recurrent non-small cell lung&#xD;
             cancer.&#xD;
&#xD;
          2. Failed previous platinum-based chemotherapy and anti-PD-(L)1 monoclonal antibody&#xD;
             treatment.&#xD;
&#xD;
          3. Have measurable disease based on RECIST v1.1.&#xD;
&#xD;
          4. ECOG PS score: 0-1.&#xD;
&#xD;
          5. Expected survival ≥ 3 months.&#xD;
&#xD;
          6. Non-surgically sterilized female subjects or women of childbearing potential must be&#xD;
             negative for a serum pregnancy test within 3 days prior to the first dose and must be&#xD;
             non-lactating. Female subjects of childbearing potential and male subjects with&#xD;
             partners of childbearing potential must agree to take highly effective contraceptive&#xD;
             measures during the study period and until 6 months after the last study dose.&#xD;
&#xD;
          7. Subjects must participate voluntarily, sign the ICF, have good compliance, and&#xD;
             cooperate with follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or&#xD;
             ascites.&#xD;
&#xD;
          2. Have known history of prior malignancy in the past 3 years.&#xD;
&#xD;
          3. Have active pulmonary tuberculosis.&#xD;
&#xD;
          4. Have clinical symptoms of the heart or heart diseases that are not well controlled.&#xD;
&#xD;
          5. Have hypertension which cannot be well controlled by antihypertensives&#xD;
&#xD;
          6. Urinalysis has indicated that the urine protein is ≥ ++ and quantitative test of urine&#xD;
             protein has confirmed that the 24-h urine protein is &gt; 1.0 g.&#xD;
&#xD;
          7. Have a thrombosis tendency or are currently receiving thrombolysis/anticoagulation&#xD;
             therapy.&#xD;
&#xD;
          8. Have received major surgery within 4 weeks prior to randomization; or palliative&#xD;
             radiotherapy within 2 weeks prior to randomization; or have not recovered from the&#xD;
             toxicities and/or complications of previous interventions to NCI-CTCAE Grade ≤ 1.&#xD;
&#xD;
          9. Have known history of arterial/venous thrombosis within 6 months prior to&#xD;
             randomization, such as cerebrovascular accidents, deep vein thrombosis and pulmonary&#xD;
             embolism.&#xD;
&#xD;
         10. Are currently participating and receiving study therapy or have participated in a&#xD;
             study and received the last dose of study drug within 4 weeks (or 5 half-lives of the&#xD;
             study drug) prior to randomization.&#xD;
&#xD;
         11. Previous treatment with camrelizumab, docetaxel, and small-molecule VEGFR inhibitors&#xD;
             including famitinib.&#xD;
&#xD;
         12. Have other potential factors that may affect the study results or result in the&#xD;
             premature discontinuation as determined by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qian Tang, M.M</last_name>
    <phone>+86 17721286353</phone>
    <email>qian.tang@hengrui.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Subei People's Hospital of Jiangsu Province</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingxiang Xu, Doctor</last_name>
      <phone>+86-18051062315</phone>
      <email>Xuxx63@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 22, 2021</study_first_submitted>
  <study_first_submitted_qc>October 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

